As it became clear that 2020 would be a year like no other, we surveyed members of our rare disease community to learn more about their attitudes and opinions around clinical trials. We wanted to find out how willing people were to take part in trials, what they felt about decentralized trial designs and whether COVID-19 had an impact on their opinions.